Real‐life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study

Real‐life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study

Abstract The real‐life retrospective observational study CARMYN aimed at investigating the long‐term efficacy and safety of carfilzomib in combination with dexamethasone and lenalidomide (KRd, 159 patients). These patients (62% in first and 38% in second relapse, median age 62 yo) were treated betwe...

Full description

Bibliographic Details
Main Authors: Kamel Laribi, Xavier Leleu, Nathalie Texier, Raphaël Germain, Cyrille Touzeau, Mohammad Hammoud, Alexandre Payssot, Samantha Schulmann, Ronan Le Calloch, Adrien Trebouet, Driss Chaoui, Selva David, Omar Benbrahim, Riad Benramdane, Anne Charvet‐Rumpler, Christelle Jadeau, Eglantine Rouanet, Olivier Decaux, Aurore Perrot
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:eJHaem
Subjects:
carfilzomib
effectiveness
real‐life evidence
refractory relapsing multiple myeloma
Online Access:https://doi.org/10.1002/jha2.828

Internet

https://doi.org/10.1002/jha2.828

Similar Items